GABAA receptor positive allosteric modulators

Fintepla (ZX008): Sold Under the Brand Name Fintepla - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Pharmaceutical, Health, Clinical trials, Drugs, Health, Clinical medicine, Orphan drugs, Anorectics, Neurological disorders, GABAA receptor positive allosteric modulators, Fenfluramine, Lennox–Gastaut syndrome, Phenobarbital

The "Fintepla (ZX008) - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fintepla (ZX008) - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • "Fintepla (ZX008)- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Lennox Gastaut Syndrome in 7 Major Markets.
  • Fintepla (ZX008) is the oral medication low-dose solution of fenfluramine hydrochloride used in the treatments to reduce the frequency of seizures.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia

Retrieved on: 
Wednesday, March 10, 2021
Chemical compounds, Branches of biology, Organic compounds, Chloroarenes, Hypnotics, Sedatives, GABAA receptor positive allosteric modulators, Lactams, Orexin, Daridorexant, Insomnia, Somnolence

The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo.

Key Points: 
  • The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo.
  • Patients reported no next-morning sleepiness compared to placebo as assessed by the morning visual analogue scale (VAS).
  • In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia.
  • Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for the treatment of insomnia.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors

Retrieved on: 
Monday, March 8, 2021
Legal, Professional services, Drugs, GABAA receptor positive allosteric modulators, Psychoactive drugs, Clinical medicine, Epilepsy, Diazepam, Seizure, Buccal, Benzodiazepine

Aquestive investors have until April 30, 2021 to file a lead plaintiff motion.

Key Points: 
  • Aquestive investors have until April 30, 2021 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors

Retrieved on: 
Friday, March 5, 2021
Legal, Professional services, Drugs, GABAA receptor positive allosteric modulators, Psychoactive drugs, Neurochemistry, Benzodiazepine, Epilepsy, Diazepam

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) securities between December 2, 2019 and September 25, 2020, inclusive (the Class Period).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) securities between December 2, 2019 and September 25, 2020, inclusive (the Class Period).
  • Aquestive investors have until April 30, 2021 to file a lead plaintiff motion.
  • Investors suffering losses on their Aquestive investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.

SHAREHOLDER ALERT: Robbins LLP Announces That Aquestive Therapeutics, Inc. (AQST) is Being Sued for Misleading Shareholders

Retrieved on: 
Thursday, March 4, 2021
Legal, Professional services, GABAA receptor positive allosteric modulators, Drugs, Psychoactive drugs, Chloroarenes, Lactams, Clinical medicine, Benzodiazepines, Anxiolytics, Diazepam, Medication, Benzodiazepine, Epilepsy

Aquestive is a specialty pharmaceutical company that develops products to address unmet medical needs.

Key Points: 
  • Aquestive is a specialty pharmaceutical company that develops products to address unmet medical needs.
  • The Company's most advanced proprietary product candidate is Libervant (diazepam), the first oral diazepam-based therapy for the treatment of recurrent epileptic seizures.
  • If you suffered a loss due to Aquestive Therapeutics, Inc.'s misconduct, click here .
  • During the relevant period, Aquestive expressed that the process for obtaining FDA approval was on target and "as expected."

The Law Offices of Frank R. Cruz Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors

Retrieved on: 
Thursday, March 4, 2021
Legal, Professional services, Drugs, GABAA receptor positive allosteric modulators, Anxiolytics, Benzodiazepines, Chloroarenes, Diazepam, Euphoriants, Epilepsy, Psychoactive drugs, Health

The Law Offices of Frank R. Cruz announces an investigation of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • Aquestive is a specialty pharmaceutical company.
  • Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

High Prescription of Psychoactive Class of Medicines for Mental Health Conditions spurs Growth in Benzodiazepine Drugs Market, Market Projected to touch Valuation of US$ 2.617 billion by 2026, TMR

Retrieved on: 
Thursday, March 4, 2021
GABAA receptor positive allosteric modulators, Psychoactive drugs, Hypnotics, Benzodiazepine, Sedatives, Benzodiazepines, Chemical compounds, Neurochemistry

Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.

Key Points: 
  • Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.
  • In 2017, the global benzodiazepine drugs market was estimated to be worth around US $ 2055 Mn.
  • The market is projected to clock a growth rate of 2.7 % CAGR over the assessment tenure, from 2018 to 2026.
  • The global benzodiazepine drugs market is being driven by an increase in the prevalence of anxiety and seizures.

High Prescription of Psychoactive Class of Medicines for Mental Health Conditions spurs Growth in Benzodiazepine Drugs Market, Market Projected to touch Valuation of US$ 2.617 billion by 2026, TMR

Retrieved on: 
Thursday, March 4, 2021
GABAA receptor positive allosteric modulators, Psychoactive drugs, Hypnotics, Benzodiazepine, Sedatives, Benzodiazepines, Chemical compounds, Neurochemistry

Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.

Key Points: 
  • Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.
  • In 2017, the global benzodiazepine drugs market was estimated to be worth around US $ 2055 Mn.
  • The market is projected to clock a growth rate of 2.7 % CAGR over the assessment tenure, from 2018 to 2026.
  • The global benzodiazepine drugs market is being driven by an increase in the prevalence of anxiety and seizures.

Global Chronic Insomnia Market to 2030 - Insights, Epidemiology, and Market Forecast - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 4, 2021
Health, Pharmaceutical, Sleep disorders, Branches of biology, Psychiatric diagnosis, GABAA receptor positive allosteric modulators, Insomnia, Chronic condition, Medicine, Flunitrazepam, Neuroscience

The "Chronic Insomnia - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Insomnia - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Chronic Insomnia market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Chronic Insomnia symptoms market size from 2017 to 2030 segmented by seven major markets.
  • The disease epidemiology covered in the report provides historical as well as forecasted Chronic Insomnia symptoms epidemiology segmented as the Prevalent cases of Chronic Insomnia, Diagnosed Prevalent cases of Chronic Insomnia, Gender-specific cases of Chronic Insomnia, and Age-specific cases of Chronic Insomnia.
  • The chronic insomnia report's drug chapter segment encloses the detailed analysis of Chronic Insomnia early-stage (Phase- I, II, and III) pipeline drugs.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors

Retrieved on: 
Wednesday, March 3, 2021
Legal, Professional services, Financial markets, Stock market, Finance, Financial economics, GABAA receptor positive allosteric modulators, Security, Epilepsy, NASDAQ, Lluís Companys, Benzodiazepine, Stock

Law Offices of Howard G. Smith announces an investigation on behalf of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) investors concerning the Companys possible violations of federal securities laws.
  • Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.
  • On this news, Aquestives stock price fell $2.64 per share, or approximately 35%, to close at $4.97 per share on September 28, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.